Introduction {#s1}
============

Adipose tissue secretes a number of peptides referred to as adipocytokines or adipokines [@pone.0052497-Galic1]. One such adipocytokine is adiponectin encoded by *ADIPOQ* (also known as *APM1*) which is involved in regulation of insulin sensitivity, carbohydrate and lipid metabolism, immunological responses, and cardiovascular functions [@pone.0052497-BrochuGaudreau1], [@pone.0052497-Nishida1]. Several studies indicated that 39%--70% of the variability in adiponectin levels is governed by genetic factors [@pone.0052497-Comuzzie1]--[@pone.0052497-Vasseur1]. During the last decade, several polymorphisms at the *ADIPOQ* locus have been tested for association with adiponectin levels [@pone.0052497-Heid1], [@pone.0052497-Hivert1]. Results of a meta-analysis and genome-wide association (GWA) studies indicated a role of variants in the *ADIPOQ* gene region in modulation of adiponectin levels [@pone.0052497-Dastani1], [@pone.0052497-Heid2]. Although this locus explains exceptionally high 2%--8% of the adiponectin levels [@pone.0052497-Heid1], [@pone.0052497-Heid2], [@pone.0052497-VozarovadeCourten1], a major fraction of heritability is still unexplained. The results of different GWA studies and linkage analyses suggested that different genomic regions are likely to be involved in regulation of adiponectin levels -- either via a primary influence or through pathways influencing body composition [@pone.0052497-Dastani1], [@pone.0052497-Heid2], [@pone.0052497-Hicks1]--[@pone.0052497-Ruchat1].

The adiponectin gene promoter region contains binding sites for various types of nuclear receptors (PPARG2, LRH, RXR), transcription factors (CEBPA, SREBP1c, TFAP2B, FOXO1, SP1) and at least three co-regulators of transcription factors (SIRT1, NCOR1 and NCOR2) [@pone.0052497-Iwaki1]--[@pone.0052497-Schaffler1]. Kita et al. demonstrated that the adiponectin promoter region from −676 to +41 is sufficient for promoter activity and that the region from −676 to −416 is crucial for basal promoter activity [@pone.0052497-Kita1]. This region consists of putative SREBP-responsive element (−676 to −416) and CEBP*-*responsive element (−416 to +41) which were both required for promoter activity. Furthermore, it was shown that FOXO1 up-regulates adiponectin gene transcription through a FOXO1-response element in the adiponectin promoter containing two adjacent FOXO1 binding sites [@pone.0052497-Qiao1]. SIRT1 increases adiponectin transcription in adipocytes by activating FOXO1 and enhancing FOXO1 and CEBPA interaction. Low expression of SIRT1 and FOXO1 can lead to impaired FOXO1-CEBPA complex formation, which might contribute to the diminished adiponectin expression in obesity [@pone.0052497-Qiao1]. PPARG2 may directly bind to the human adiponectin promoter by forming heterodimers with RXR and increase adiponectin promoter activity [@pone.0052497-Iwaki1]. Moreover, promoter activity of the adiponectin gene is inhibited by over-expression of TFAP2B and enhanced by knockdown of its endogenous expression [@pone.0052497-Maeda1].

These lines of evidence indicate that several transcription factors and their co-regulators are involved in adiponectin gene expression: some through binding to the adiponectin promoter and increasing promoter activity, others through negative regulation of adiponectin gene expression. Taking this into consideration, we hypothesized that genetic polymorphisms in these gene regions may influence adiponectin gene transcription and adiponectin levels. To evaluate this hypothesis, we performed association analyses on the relation of selected polymorphisms in main adiponectin transcription factors for adiponectin promoter with the adiponectin levels in three different European cohorts.

Materials and Methods {#s2}
=====================

Study Populations {#s2a}
-----------------

### SAPHIR Study {#s2a1}

The SAPHIR study has been initiated in the year 1999 as a population-based prospective study that investigates genetic and environmental factors contributing to atherosclerotic vascular diseases [@pone.0052497-Heid1]. Study participants were recruited by a health screening programs in large companies in and around the city of Salzburg, Austria. The study comprises 1770 healthy unrelated Caucasian subjects (663 females and 1107 males aged 39--67 years). At baseline, all participants were subjected to a comprehensive examination -- detailed personal and family history, physical, instrumental and laboratory investigations. Serum adiponectin levels were measured by an enzyme-linked immunosorbent assay kit from BioCat (Heidelberg, Germany). DNA was available from 1760 participants and all relevant variables for analyses were available for 1742 participants.

### KORA F3 Study {#s2a2}

The KORA F3 Study is the 10 year follow-up of the third survey from the KORA-Study (Cooperative Health Research in the Region of Augsburg), a population-based sample from the general population of the South-German city of Augsburg and surrounding counties from 1994/1995. The KORA surveys have been described in detail previously [@pone.0052497-Wichmann1]. Genome-wide genotype data were available for a subsample of 1644 individuals with all relevant variables available for 1636 individuals. Serum levels of adiponectin were measured by ELISA from Mercodia (Uppsala, Sweden).

### CoLaus Study {#s2a3}

The CoLaus study is a single-center, cross-sectional study which included 6188 Caucasian subjects aged 35 to 75 years from the city of Lausanne in Switzerland [@pone.0052497-Firmann1]. The major goal of the CoLaus study is investigation of prevalence, severity and molecular architecture of cardiovascular risk factors in a Lausanne population. Recruitment began in June 2003 and ended in May 2006. For 5435 participants, genome-wide genotype data are available. The current analysis included 5355 extensively phenotyped participants from this study. Plasma adiponectin levels were measured using the ELISA assay from R&D Systems (MN, USA).

Ethics Statement {#s2b}
----------------

All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. Participants from all 3 studies provided written informed consent and the studies were approved by the local ethical committees (SAPHIR Study, Ethical Committee of Land Salzburg; KORA F3, local ethical committee of Bayerische Landesärztekammer; CoLaus, Institutional Ethic's Committee of the University of Lausanne).

Selection of Transcription Factors {#s2c}
----------------------------------

Three main transcription factors acting on the adiponectin promoter (FOXO1, SREBP1c, TFAP2B) were selected based on previously published data on their important role in regulation of human adiponectin promoter activity or association of genetic polymorphisms at these genes with adiponectin levels [@pone.0052497-Kita1], [@pone.0052497-Qiao1], [@pone.0052497-Felder1], [@pone.0052497-Ikeda1]. CEBPA was excluded from our consideration because of controversial data about the CEBPA binding site at the adiponectin gene promoter or intron I [@pone.0052497-Kita1], [@pone.0052497-Qiao2], [@pone.0052497-Segawa1] and lack of evidence for a role of genetic variation at this locus in control of adiponectin levels. One co-regulator of transcription factors (SIRT1) was added based on its interaction with FOXO1 in regulation of adiponectin expression [@pone.0052497-Qiao1].

SNP Selection {#s2d}
-------------

Genotype data of the main transcription factors *(FOXO1, SREBF1, TFAP2B*) and one co-regulator of the transcription factors (*SIRT1*) for adiponectin promoter were downloaded from HapMap Data (Phase III/Rel.\#2, Feb 09) (<http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap3r2_B36/>). Then data were transferred to SNP tagger (<http://www.broad.mit.edu/mpg/tagger/server.html>) to identify haplotype-tagging SNPs.

Using the haplotype block structure we selected a maximally informative subset of validated SNPs with minor allele frequency of ≥5% and pairwise r^2^≥80% (*FOXO1* MAF = 10%, r^2^ = 80%; *SREBF1* MAF = 5%, r^2^ = 100%; *TFAP2B* MAF = 5%, r^2^ = 80%; *SIRT1* MAF = 5%, r^2^ = 80%). Haplotype frequencies in each gene were estimated by implementation of the expectation maximization algorithm. Four SNPs (rs2236319, rs3740051 at *SIRT1,* rs987237 at *TFAP2B and* rs1801282 at *PPARG)* were included additionally based on the previous publications [@pone.0052497-Helisalmi1]--[@pone.0052497-Yamamoto1].

Genotyping {#s2e}
----------

Genomic DNA was isolated from whole blood in all three populations according to manufacturer's protocols. Genotyping in SAPHIR cohort was performed using 5\' nuclease allelic discrimination TaqMan genotyping method and pre-designed assays from Applied Biosystems (Foster City, CA, USA) according to the manufacturer's instructions.

After the SNPs have been genotyped in SAPHIR, in-silico replication has been performed in the KORA F3 and CoLaus cohorts. For both populations, imputed genome-wide genotypes are available from which the respective SNPs were selected. Original genotyping for KORA F3 and CoLaus studies were performed using the Affymetrix GeneChip Human Mapping 500K Array Set (Affymetrix, Santa Clara, USA). Genotypes were determined using the BRLMM clustering algorithm (Bayesian Robust Linear Modeling using Mahalanobis distance, Affymetrix 500K Array Set) [@pone.0052497-Sandhu1]. Imputation of genotypes was performed with the software MACH v1.0.9 [@pone.0052497-Li1] in KORA F3 and IMPUTE version 0.2.0 [@pone.0052497-Marchini1] in the CoLaus study.

Statistical Analysis {#s2f}
--------------------

In each study population, the association of each SNP with log-transformed adiponectin levels using linear regression models adjusted for age, sex and body mass index (BMI) applying an additive as well as recessive genetic model was analyzed. The analyses were also conducted stratified for sex, in this case only adjusting for age and BMI. A pooled effect size for all participants as well as for men and women separately was obtained by meta-analysis assuming a fixed effects model. The possibility of sex-specific effects has been tested on each SNP using a t-test based on the meta-analyzed effect estimates and standard errors on the original scale of adiponectin [@pone.0052497-Teslovich1].

Correction for multiple testing was applied on independent number of tests for the main analyses (additive model). This number was calculated using the effective number of loci [@pone.0052497-Li2], which accounts for the correlation structure between the SNPs. The percentage of explained variance per SNP and pair-wise linkage disequilibrium (LD) between SNPs (D\' and R^2^) was obtained using data from the SAPHIR study only. Also in SAPHIR, haplotypes were estimated for all genes except *PPARG* by the expectation maximization algorithm using the haplo.stats package <http://CRAN.R-project.org/package=haplo.stats>) in the R software environment [@pone.0052497-Sinnwell1]. Subsequent association analysis of the number of haplotype copies on log-transformed adiponectin was adjusted for age, sex and BMI.

Results {#s3}
=======

Patient and Genotype Characteristics {#s3a}
------------------------------------

Clinical characteristics and adiponectin levels of the three study populations are presented in [Table 1](#pone-0052497-t001){ref-type="table"}. All three study populations were comparable with respect to the phenotype studied and adjusting variables with the exception of the higher mean age and higher rate of type 2 diabetes (T2D) in the KORA F3 Study. There was a higher frequency of male participants in the SAPHIR population (62.7%) compared KORA F3 (49.5%) and CoLaus cohorts (47.3%).

10.1371/journal.pone.0052497.t001

###### Clinical characteristics of the subjects from SAPHIR, KORA F3 and CoLaus studies (means ± SD or numbers (%)), for whom all relevant variables and genotypes are available.

![](pone.0052497.t001){#pone-0052497-t001-1}

  Parameters                SAPHIR        KORA F3        CoLaus
  --------------------- -------------- ------------- --------------
  Number                     1742          1636           5355
  Male individuals       1092 (62.7%)   809 (49.5%)   2531 (47.3%)
  Age (years)              51.4±6.0      62.5±10.1     53.4±11.0
  BMI (kg/m^2^)            26.8±4.1      28.1±4.5       25.8±4.5
  Adiponectin (µg/ml)     8.58±4.58     10.61±4.65     10.05±8.00
  Type 2 Diabetes (%)     58 (3.3%)     179 (10.9%)    348 (6.5%)

Initially, we genotyped 24 SNPs at *FOXO1*, *SREBF1*, *PPARG*, *TFAP2B* and *SIRT1* genes in SAPHIR cohort and added in-silico replication of the respective SNPs using the imputed genotypes from KORA F3 and CoLaus. [Table 2](#pone-0052497-t002){ref-type="table"} shows the corresponding descriptive statistics of the genotypes. The minor allele frequencies were comparable between all three populations. Issues regarding the genotyping quality could only be detected in four SNPs. In *TFAP2B* gene rs2143079 was poorly imputed (imputation quality score RSQR\<60% in both in KORA F3 and CoLaus) and rs1569777 showed a deviation from the Hardy-Weinberg equilibrium in SAPHIR. Also in *FOXO1,* two SNPs (rs10507486 and rs17446614) had a deviation from the Hardy-Weinberg equilibrium in SAPHIR cohort ([Table 2](#pone-0052497-t002){ref-type="table"}).

10.1371/journal.pone.0052497.t002

###### Characteristics of the 24 SNPs in SAPHIR, KORA F3 and CoLaus, including genotype quality (call rate or imputation quality RSQR).

![](pone.0052497.t002){#pone-0052497-t002-2}

                  Alleles   SAPHIR (n = 1760)   KORA F3 (n = 1644)   CoLaus (n = 5435)                                                                                 
  -------------- --------- ------------------- -------------------- ------------------- ------- ------- ------------- ------- ------- ------- ---------------- ------- -------
  ***FOXO1***                                                                                                                                                          
  rs10507486       *A/G*          0.203            1135/529/91             0.006         0.997   0.216   1016/546/82   0.424   0.999   0.194   3543/1673/219    0.206   1.000
  rs17446593       *G/A*          0.178            1186/513/55             1.000         0.997   0.177   1111/483/50   0.866   0.905   0.168   3781/1478/174    0.027   0.943
  rs17446614       *A/G*          0.155            1259/430/55             0.017         0.991   0.167   1144/451/49   0.594   1.000   0.153   3916/1378/141    0.155   1.000
  rs2297627        *G/A*          0.304            867/710/180             0.055         0.998   0.310   788/692/164   0.526   1.000   0.309   2616/2280/539    0.179   1.000
  rs2721068        *C/T*          0.260            958/666/121             0.709         0.991   0.258   902/636/106   0.699   0.963   0.254   3061/1982/391    0.005   0.977
  ***PPARG***                                                                                                                                                          
  rs1801282        *G/C*          0.137            1309/413/35             0.688         0.998   0.143   1203/411/30   0.546   0.997   0.118    4248/1095/92    0.030   1.000
  ***SIRT1***                                                                                                                                                          
  rs10823108       *A/G*          0.063             1546/203/9             0.414         0.999   0.074   1410/224/10   0.718   0.998   0.065    4757/649/29     0.176   0.998
  rs12413112       *A/G*          0.120            1365/363/29             0.367         0.998   0.138   1220/395/29   0.755   0.996   0.124    4174/1174/87    0.850   0.996
  rs1467568        *A/G*          0.340            769/768/209             0.424         0.992   0.362   679/739/226   0.286   0.998   0.336   2390/2433/611    0.759   0.997
  rs2236319        *G/A*          0.063             1543/207/7             1.000         0.998   0.074   1412/222/10   0.716   0.999   0.065    4759/647/29     0.141   0.997
  rs2273773        *C/T*          0.063             1544/205/8             0.683         0.998   0.074   1410/224/10   0.718   0.943   0.067    4738/667/30     0.176   0.972
  rs3740051        *G/A*          0.063             1546/204/8             0.682         0.999   0.073   1413/221/10   0.589   0.999   0.065    4759/646/29     0.141   0.997
  ***SREBF1***                                                                                                                                                         
  rs11656665       *G/A*          0.383            657/847/246             0.336         0.994   0.387   618/778/248   0.917   0.942   0.404   1939/2589/898    0.445   0.952
  rs11868035       *A/G*          0.303            845/750/155             0.571         0.994   0.301   796/705/143   0.482   0.882   0.309   2582/2329/515    0.704   0.866
  rs1889018        *G/A*          0.378            671/831/246             0.684         0.993   0.391   610/783/251   1.000   0.981   0.404   1948/2583/904    0.409   0.994
  rs2236513        *A/C*          0.373            690/812/247             0.759         0.994   0.384   622/783/239   0.794   0.980   0.399   1987/2558/890    0.172   0.984
  rs2297508        *C/G*          0.365            705/820/230             0.757         0.997   0.372   652/762/230   0.752   0.909   0.387   2054/2532/838    0.207   0.900
  ***TFAP2B***                                                                                                                                                         
  rs1569777        *T/C*          0.117            1406/278/66             0.000         0.994   0.109   1307/315/22   0.526   0.936   0.126    4145/1208/81    0.393   0.957
  rs2076309        *T/C*          0.432            555/885/316             0.264         0.998   0.450   504/802/338   0.584   0.988   0.455   1609/2702/1124   0.867   0.988
  rs2143079        *G/C*          0.052             1578/179/2             0.231         0.999   0.063   1440/202/2    0.087   0.540   0.054    4865/553/16     1.000   0.574
  rs2206277        *T/C*          0.202            1117/563/73             0.825         0.996   0.165   1147/451/46   0.858   0.922   0.149   3928/1388/118    1.000   0.957
  rs2857506        *A/G*          0.117            1338/358/22             0.816         0.976   0.113   1294/330/20   1.000   0.949   0.105    4350/1025/60    0.881   0.974
  rs7771651        *T/A*          0.145            1280/441/34             0.631         0.997   0.150   1185/424/35   0.772   0.992   0.161   3811/1497/127    0.212   0.985
  rs987237         *G/A*          0.199            1123/571/64             0.454         0.999   0.164   1150/449/45   0.857   0.929   0.149   3933/1384/117    1.000   0.961

Minor and Major alleles based on the plus-strand.

Number of homozygotes for the major allele/heterozygotes/homozygotes for the rare allele; For KORA F3 and CoLaus, where imputed genotype scores have been used, this are the numbers of the "best guess" genotypes (KORA F3) and rounded sum of genotype scores.

Based on exact test of Hardy-Weinberg Equilibrium (HWE).

Association Analysis {#s3b}
--------------------

We evaluated the association of genetic variants in the main transcription factors (*FOXO1*, *SREBF1*, *PPARG*, *TFAP2B*) and their co-regulator (*SIRT1*) for *ADIPOQ* promoter with adiponectin level. Meta-analysis of additive linear regression models adjusted for age, sex, and BMI revealed association with log(adiponectin) in all 5 selected SNPs in the *SREBF1* gene. After calculating the number of independent SNPs, which is 15 out of the 24 selected SNPs, and correcting for multiple testing (α = 0.05/15 = 0.0033) two SNPs from the *SREBF1* gene remained significant: rs1889018 (p = 0.002) and rs2236513 (p = 0.003). [Table 3](#pone-0052497-t003){ref-type="table"} shows the results for all three populations as well as the combined effects. For rs1889018, for example, each copy of the minor allele leads to a reduction of the adiponectin level of 0.217 µg/ml. This corresponds to an explained variance of ∼0.4% as calculated from the SAPHIR Study. All selected SNPs within *SREBF1* are highly correlated ([Figure 1](#pone-0052497-g001){ref-type="fig"}).

![Linkage disequilibrium structure across the *SREBF1* single nucleotide polymorphisms.\
The pair wise linkage disequilibrium (R^2^ and D') is given for each pair of single nucleotide polymorphisms. Color-coding is based on R^2^. The diagonal line indicates the physical position of the single nucleotide polymorphisms relative to each other.](pone.0052497.g001){#pone-0052497-g001}

10.1371/journal.pone.0052497.t003

###### Linear model results on the 24 selected SNPs in the SAPHIR, KORA F3 and CoLaus study using an additive genetic model, adjusted for age, sex and BMI, as well as the combined fixed effects meta-analysis results.
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                  SAPHIR (n = 1742)   KORA F3 (n = 1636)   CoLaus (n = 5355)   Meta-analysis results   Meta-analysis results, separated for menand women, t-test on difference                                                                        
  -------------- ------------------- -------------------- ------------------- ----------------------- ------------------------------------------------------------------------- ------ ---------------- ----------- ---------------- ---------------- -------
  ***FOXO1***                                                                                                                                                                                                                                         
  rs10507486        0.23 (0.164)             0.23           −0.169 (0.175)             0.62                                         −0.075 (0.18)                                0.70    0.007 (0.1)       0.80      0.003 (0.107)    −0.007 (0.173)   0.96
  rs17446593       −0.161 (0.178)            0.28            0.006 (0.191)             0.60                                         0.07 (0.195)                                 0.89   −0.036 (0.108)     0.98      −0.009 (0.116)   −0.047 (0.189)   0.84
  rs17446614       −0.092 (0.183)            0.56           −0.123 (0.194)             0.87                                        −0.026 (0.197)                                0.99   −0.081 (0.11)      0.90      0.031 (0.118)    −0.208 (0.193)   0.21
  rs2297627         0.037 (0.144)            0.56           −0.136 (0.156)             0.61                                        −0.099 (0.154)                                0.35   −0.06 (0.087)      0.40      −0.003 (0.094)   −0.129 (0.151)   0.40
  rs2721068        −0.167 (0.154)            0.51           −0.046 (0.167)             0.82                                        −0.073 (0.163)                                0.48   −0.099 (0.093)     0.46      0.009 (0.101)    −0.211 (0.161)   0.17
  ***PPARG***                                                                                                                                                                                                                                         
  rs1801282        −0.197 (0.195)            0.25            0.135 (0.21)              0.33                                         0.103 (0.22)                                 0.87    0.001 (0.12)      0.89      −0.235 (0.129)   0.288 (0.208)    0.012
  ***SIRT1***                                                                                                                                                                                                                                         
  rs10823108        −0.17 (0.277)            0.83           −0.155 (0.276)             0.38                                         0.453 (0.288)                                0.12   0.032 (0.162)      0.30      −0.06 (0.169)    0.171 (0.291)    0.42
  rs12413112        0.033 (0.206)            0.69           −0.051 (0.212)             0.81                                         0.083 (0.217)                                0.56   0.021 (0.122)      0.82      −0.117 (0.13)    0.162 (0.216)    0.19
  rs1467568         0.023 (0.142)            0.55            0.054 (0.149)             0.83                                         0.202 (0.152)                                0.08   0.089 (0.085)      0.04      0.098 (0.091)    0.095 (0.149)    0.98
  rs2236319        −0.168 (0.279)            0.94            −0.15 (0.277)             0.41                                         0.455 (0.288)                                0.13   0.036 (0.162)      0.31      −0.045 (0.171)   0.161 (0.291)    0.47
  rs2273773        −0.166 (0.278)            0.90           −0.155 (0.276)             0.38                                         0.443 (0.288)                                0.12    0.03 (0.162)      0.28      −0.051 (0.17)    0.158 (0.291)    0.47
  rs3740051         −0.22 (0.278)            0.58           −0.126 (0.277)             0.47                                         0.455 (0.288)                                0.13   0.026 (0.162)      0.36      −0.103 (0.17)     0.206 (0.29)    0.28
  ***SREBF1***                                                                                                                                                                                                                                        
  rs11656665       −0.317 (0.141)           0.011           −0.108 (0.149)             0.31                                         −0.087 (0.15)                                0.08   −0.177 (0.085)     0.007     −0.139 (0.091)   −0.223 (0.148)   0.57
  rs11868035       −0.335 (0.149)           0.003           −0.202 (0.160)             0.18                                         −0.2 (0.167)                                 0.10   −0.252 (0.091)     0.004     −0.147 (0.098)   −0.365 (0.161)   0.17
  rs1889018        −0.422 (0.141)           0.001           −0.120 (0.149)             0.27                                         −0.09 (0.146)                                0.06   −0.217 (0.084)   **0.002**   −0.189 (0.089)   −0.247 (0.147)   0.69
  rs2236513        −0.443 (0.140)           0.001           −0.114 (0.150)             0.28                                        −0.069 (0.147)                                0.09   −0.218 (0.084)   **0.003**   −0.159 (0.09)    −0.277 (0.147)   0.42
  rs2297508        −0.398 (0.141)           0.001           −0.145 (0.150)             0.23                                        −0.071 (0.154)                                0.12   −0.215 (0.086)     0.005     −0.136 (0.092)   −0.308 (0.15)    0.25
  ***TFAP2B***                                                                                                                                                                                                                                        
  rs1569777         0.134 (0.189)            0.48            0.379 (0.231)             0.13                                         0.234 (0.222)                                0.72   0.233 (0.122)      0.66      0.077 (0.133)    0.379 (0.211)    0.15
  rs2076309         0.023 (0.138)            0.76           −0.185 (0.145)             0.20                                        −0.083 (0.145)                                0.64   −0.079 (0.082)     0.34      −0.043 (0.088)   −0.132 (0.144)   0.54
  rs2143079         0.363 (0.31)             0.13           −0.632 (0.307)             0.03                                        −0.445 (0.421)                                0.11   −0.204 (0.193)     0.08      −0.088 (0.212)   −0.405 (0.334)   0.34
  rs2206277        −0.087 (0.169)            0.93            0.409 (0.197)             0.11                                         0.093 (0.206)                                0.54   0.115 (0.109)      0.28      0.082 (0.116)    0.212 (0.193)    0.50
  rs2857506        −0.055 (0.213)            0.94           −0.207 (0.231)             0.38                                        −0.085 (0.236)                                0.43   −0.113 (0.131)     0.64      −0.119 (0.139)   −0.098 (0.231)   0.93
  rs7771651         0.008 (0.194)            0.97           −0.167 (0.205)             0.90                                        −0.061 (0.199)                                0.76   −0.07 (0.115)      0.74      −0.018 (0.139)   −0.162 (0.203)   0.48
  rs987237         −0.051 (0.172)            0.85            0.431 (0.197)             0.09                                         0.094 (0.206)                                0.53    0.139 (0.11)      0.23      0.085 (0.116)    0.263 (0.195)    0.36

Effect estimates and standard errors (for the combined as well as sex-specific analyses) are based on the original adiponectin scale, whereas p-values are taken from the linear regression on log(adiponectin).

Recessive effect models as well as haplotype analyses did not provide any additional information (data not shown). There was also no significant sex-specific effect in regulation of adiponectin levels for SNPs in *FOXO1*, *SREBF1*, *TFAP2B* and *SIRT1* genes. Comparison of men-specific and women-specific data, however, showed a sex-difference in rs1801282 (*PPARG*, p for sex-difference  = 0.012), though this cannot be deemed significant given the number of tests involved. Nevertheless, it was interesting to see a negative effect in men (β = −0.235, p = 0.212), while the effect was positive in women (β = 0.288, p = 0.177).

Discussion {#s4}
==========

Considering that transcriptional control of the *ADIPOQ* is one of the most important factors involved in regulation of adiponectin levels, we hypothesized that genetic variation at the loci encoding the main transcription factors controlling activity of the adiponectin promoter might be involved in regulation of adiponectin levels. We therefore performed association analyses of the 24 selected SNPs from 5 different transcription factors. We observed a modest influence of genetic polymorphisms at the *SREBF1* gene on the adiponectin levels in three healthy West-Eurasian populations including 8733 individuals, but not for the other transcription factors (*FOXO1, SIRT1, TFAP2B* and *PPARG)*. Two of the five investigated polymorphisms (rs1889018 and rs2236513) at the *SREBF1* gene locus demonstrated an influence on the adiponectin levels even after adjustment for multiple testing with lower concentrations in carriers of the minor allele. Additionally, our data revealed a sex-specific effect of the *Pro12Ala* SNP at the *PPARG* locus on adiponectin levels. The minor allele (*Ala*) of this gene negatively correlated with adiponectin levels in men, but positively in women. This finding was not significant after correction for multiple testing.

In previous publications the role of genetic polymorphisms of the transcription factors controlling *ADIPOQ* promoter activity in regulation of adiponectin levels was not investigated in detail -- moreover the haplotype structure of these genes and sex-related effects (with the exception of *PPARG)* were not taken into consideration. Few years ago, Felder et al. using data from the SAPHIR cohort and additionally 446 unrelated patients with T2D discovered an association between one SNP at the *SREBF1* gene (rs2297508) and the prevalence of T2D and adiponectin levels [@pone.0052497-Felder1]. In our study we extended the analysis of genetic polymorphisms at the *SREBF1* gene including additionally two cohorts and 4 SNPs, three of them having been selected as haplotype-tagging SNPs and one (rs2236513) based on literature data [@pone.0052497-Harding1]. In our meta-analysis of 3 cohorts the two SNPs located in the 5\'-UTR of the gene showed the strongest association with adiponectin levels ([Figure 2](#pone-0052497-g002){ref-type="fig"}). However, it should be noted, that all selected SNPs within *SREBF1* are highly correlated ([Figure 1](#pone-0052497-g001){ref-type="fig"}). Therefore, it can be assumed that the different hits within this gene refer to the same signal or signals. The search for the effect-triggering variants still requires further investigation. The identified SNPs at the *SREBF1* gene locus do not directly change its protein structure. They could, however, change various aspects of mRNA metabolism such as alterations of regulatory RNA-binding protein sites and mRNA secondary structure, that may influence functional properties of *SREBP1*c mRNA. It cannot be excluded that these SNPs are in linkage disequilibrium with yet unidentified functional mutations, either in the *SREBF1* gene or a gene located in that region.

![Schematic structure of *SREBF1* gene.\
Exons are numbered indicating the alternatively spliced -a and -c variants. Genomic location of the analyzed single nucleotide polymorphisms are marked. The single nucleotide polymorphisms highlighted in yellow showed a strongly associated with adiponectin levels in our study. The single nucleotide polymorphism highlighted in grey showed a significant association in a previous study [@pone.0052497-Felder1] and was only borderline significantly associated in the present study (p = 0.004).](pone.0052497.g002){#pone-0052497-g002}

The PPARG2 is a ligand-activated transcription factor, which acts as a heterodimer with the RXR [@pone.0052497-Kersten1], [@pone.0052497-Stumvoll1]. PPARG2 has been shown to increase transcription of the *ADIPOQ* gene and many other genes that are involved in the pathogenesis of insulin resistance [@pone.0052497-Iwaki1], [@pone.0052497-Liu1], [@pone.0052497-Rangwala1]. Agonist-induced activation of PPARG is known to cause adipocyte differentiation, improvement in insulin sensitivity and also increased secretion of adiponectin by adipose tissue [@pone.0052497-Kawada1], [@pone.0052497-Spiegelman1]. The most frequently analysed and most well documented SNP in the *PPARG* gene is a proline to alanine substitution (*Pro12Ala*) in codon 12 of exon B (15% frequency among Caucasians). This substitution has a protective effect against the development of T2D. The *Ala* receptor variant is less efficient in its ability to bind and trans-activate a PPARG2 target gene in vitro [@pone.0052497-Sharma1]. The proline to alanine amino acid change also might affect the secondary structure of the protein and its functionality [@pone.0052497-Gouda1]. Heikkinen et al. (2009) suggested that the *Pro12Ala* polymorphism might be involved in the function of G protein, in sensitization of adiponectin signalling and altered recruitment of cofactors [@pone.0052497-Heikkinen1].

Yamamoto et al. investigated the effect of the *PPARG Pro12Ala* polymorphism on metabolic parameters and adiponectin levels in 598 Japanese people and found that adiponectin levels were significantly lower in subjects with the *Ala12* allele [@pone.0052497-Yamamoto1]. However, a Finnish study demonstrated that adiponectin levels were significantly higher among *PPARG*-*Ala* allele carriers after weight loss induced by heavy exercises [@pone.0052497-Mousavinasab1]. In our study, we could not confirm an influence of the *Pro12Ala* polymorphism at the *PPARG* gene on adiponectin levels. Nevertheless, sex-specific effects of this SNP on adiponectin levels were observed indicating a positive correlation in women and a negative in men. The mechanism underlying this sex-specific effect of the *PPARG* gene in regulating adiponectin levels and various metabolic traits is currently not known. Sexual dimorphisms have frequently been reported in relation to fat distribution and have been evidenced for genes that affect BMI. Men are more likely to gain visceral fat and deep subcutaneous fat than women [@pone.0052497-Bjorntorp1]--[@pone.0052497-Smith1]. Taking into consideration that women have more subcutaneous fat as compared to men and PPARG2 expression is more pronounced in subcutaneous adipose tissue [@pone.0052497-GonzalezSanchez1]--[@pone.0052497-VidalPuig1], one can speculate that sex-specific effects of this polymorphism on adiponectin levels are related to differences in fat distribution between men and women.

Our data did not reveal any effect of genetic polymorphisms at the *FOXO1*, *TFAP2B* and *SIRT1* gene loci on adiponectin levels. This might be explained by their minor role in the process of transcriptional regulation of the adiponectin gene or the investigated polymorphisms do not have sufficient influence on the structure of these transcription factor proteins.

Previous linkage studies suggested that different genetic components might be involved in the regulation of adiponectin levels, but their replications were inconsistent across different ethnic populations [@pone.0052497-Lindsay1], [@pone.0052497-Hicks1], [@pone.0052497-Ling1]--[@pone.0052497-Ruchat1], [@pone.0052497-Bowden1]--[@pone.0052497-Guo1]. Also the genetic variants detected in GWA studies did not explain the high level of heritability of adiponectin levels. The first GWA study was conducted in a European population and showed strong associations of adiponectin levels with *ADIPOQ* and *CDH13* loci [@pone.0052497-Ling1]. Later, Richards et al. in a meta-analysis of three GWA studies confirmed *ADIPOQ* and revealed a new locus - *ARL15* (rs4311394) [@pone.0052497-Richards1]. In 2010, Wu et al. provided a strong evidence of association with adiponectin for three loci: *ADIPOQ*, *CDH13* and *KNG1* together explained 7.5% and 8.9% of the variability of log-transformed adiponectin levels in Filipino women and their offspring, respectively. The strongest signal mapped to the *CDH13* and explained approximately 4% of the variability of adiponectin levels [@pone.0052497-Wu1]. The association of *CDH13* locus with adiponectin levels was later confirmed in another GWA studies [@pone.0052497-Jee1], [@pone.0052497-Chung1], [@pone.0052497-Morisaki1]. In a recent meta-analysis of GWA studies, 10 novel loci for adiponectin levels were identified and confirming the associations with variants at the *ADIPOQ* and *CDH13* loci [@pone.0052497-Dastani1]. The genes included in our study were not detected in the previously published GWA studies. Possible explanations for this finding might be the different principles of SNP selection (candidate gene approach in our study vs. use of common genetic determinants across the genome in GWA studies) and the much higher threshold for significance (p\<10^−8^) used in GWA studies.

Strengths and Limitations of the Study {#s4a}
--------------------------------------

The strength of our study is the selection of candidate genes based on the known regulatory mechanisms of adiponectin gene transcription. Additionally, we used the haplotype structure of the candidate genes for SNP selection with the addition of previously reported SNPs, allowing coverage of the whole gene region instead of single SNPs in the gene region. Finally, we could show direction-consistent significant effects for two SNPs in *SREBF1* gene in three European populations, including a total number of 8733 participants.

Nevertheless, several limitations of this work should be noted. The differences in mean age, proportion of male participants and subjects with T2D between the three populations studied might have influenced adiponectin levels [@pone.0052497-Wu1], [@pone.0052497-Kadowaki1]. Also we did not take into consideration the genetic polymorphisms of all transcription factors known to be important for the adiponectin promoter, but included only four main transcription factors and one co-regulator based which have been found to be of greatest importance in regulation of adiponectin promoter activity and adiponectin levels. Finally, the study size was too small to performed analyses stratified for T2D or obesity.

Conclusion {#s4b}
----------

From the 24 selected SNPs at the five investigated transcription factors important for regulation of the adiponectin gene promoter, only those at the *SREBF1* gene had a modest influence on adiponectin levels in three healthy West-Eurasian populations. The role of genetic variations at the *SREBF1* gene and possible sex-related effects of *PPARG* in regulation of adiponectin levels have to be investigated in functional studies. Understanding the genetic mechanisms regulating adiponectin levels will expand our present knowledge concerning the factors that influence adiponectin levels. This could also lead to new therapeutic strategies to normalize circulating levels of adiponectin in subjects with metabolic disorders and cardiovascular disease.
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